The company specializes in the development of antibody-based drug candidates for the treatment of cancer, using innovative technologies and expertise in antibody research. They develop drugs such as monoclonal antibodies and double antibodies, and their proprietary technology, APB-A001, aids in chemotherapy, immunotherapy, and radiotherapy for cancer treatment. Their goal is to address the unmet medical needs of patients and contribute to the advancement of precision medicine.